These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8782148)

  • 1. Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
    Isaacs JD; Hazleman BL; Chakravarty K; Grant JW; Hale G; Waldmann H
    J Rheumatol; 1996 Jun; 23(6):1103-6. PubMed ID: 8782148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).
    Walsh M; Chaudhry A; Jayne D
    Ann Rheum Dis; 2008 Sep; 67(9):1322-7. PubMed ID: 18055469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD.
    Wolff D; Steiner B; Stilgenbauer S; Kahl C; Leithäuser M; Junghanss C; Wilhelm S; Kleine HD; Zimmermann R; Hartung G; Casper J; Freund M
    Eur J Haematol; 2004 Feb; 72(2):145-8. PubMed ID: 14962253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Campath-1H.
    Sorokin P
    Clin J Oncol Nurs; 2001; 5(2):65-6. PubMed ID: 11899778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.
    Lockwood CM; Hale G; Waldman H; Jayne DR
    Rheumatology (Oxford); 2003 Dec; 42(12):1539-44. PubMed ID: 12949252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients.
    Knechtle SJ
    Pediatr Transplant; 2004 Apr; 8(2):106-12. PubMed ID: 15049789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission induced by Campath-1H for thymoma-associated agranulocytosis.
    Alvares CL; Svasti-Salee D; Rowley M; Gordon-Smith EC; Marsh JC
    Ann Hematol; 2004 Jun; 83(6):398-400. PubMed ID: 14689236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients.
    Csapo Z; Benavides-Viveros C; Podder H; Pollard V; Kahan BD
    Transplant Proc; 2005 Jun; 37(5):2032-6. PubMed ID: 15964331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab (Campath-1H) for treatment of refractory polymyositis.
    Thompson B; Corris P; Miller JA; Cooper RG; Halsey JP; Isaacs JD
    J Rheumatol; 2008 Oct; 35(10):2080-2. PubMed ID: 18843768
    [No Abstract]   [Full Text] [Related]  

  • 12. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
    Coles A; Deans J; Compston A
    Clin Neurol Neurosurg; 2004 Jun; 106(3):270-4. PubMed ID: 15177782
    [No Abstract]   [Full Text] [Related]  

  • 13. Campath-1H therapy in refractory ocular inflammatory disease.
    Dick AD; Meyer P; James T; Forrester JV; Hale G; Waldmann H; Isaacs JD
    Br J Ophthalmol; 2000 Jan; 84(1):107-9. PubMed ID: 10611109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection.
    Heider U; Fleissner C; Zavrski I; Jakob C; Dietzel T; Eucker J; Ockenga J; Possinger K; Sezer O
    Eur J Haematol; 2004 Jan; 72(1):64-6. PubMed ID: 14962266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
    Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
    Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo CAMPATH-1 monoclonal antibodies: a novel mode of therapy for acute graft-versus-host disease.
    Varadi G; Or R; Slavin S; Nagler A
    Am J Hematol; 1996 Jul; 52(3):236-7. PubMed ID: 8756101
    [No Abstract]   [Full Text] [Related]  

  • 18. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of Campath 1H induction in adult liver allotransplantation.
    Tryphonopoulos P; Madariaga JR; Kato T; Nishida S; Levi DM; Moon J; Selvaggi G; De Faria W; Regev A; Bejarano P; Khaled A; Safdar K; Esquenazi V; Weppler D; Yoshida H; Ruiz P; Miller J; Tzakis AG
    Transplant Proc; 2005 Mar; 37(2):1203-4. PubMed ID: 15848669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful use of Campath-1H in the treatment of steroid refractory liver GvHD.
    Wandroo F; Auguston B; Cook M; Craddock C; Mahendra P
    Bone Marrow Transplant; 2004 Aug; 34(3):285-7. PubMed ID: 15170160
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.